 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Efficacy and safety of camrelizumab plus chemotherapy as preoperative adjuvant therapy for locally advanced esophageal cancer

J Immunother Cancer: Efficacy and safety of camrelizumab plus chemotherapy as preoperative adjuvant therapy for locally advanced esophageal cancer

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

filariasis treatment

risperidone 1 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Both camrelizumab (Erica) and chemotherapy as first-line therapy in patients with advanced esophageal squamous cell carcinoma (ESCC) have shown durable antitumor activity and manageable safety profiles
.

This study aimed to evaluate the efficacy and safety of camrelizumab combined with neoadjuvant chemotherapy in the treatment of locally advanced ESCC

Patients with locally advanced but surgically resectable thoracic esophageal squamous cell carcinoma with stage T1b-4a, N2-3 (≥ level 3), M0, or M1 lymph node metastases (limited to supraclavicular lymph nodes) were recruited
.

Two courses of study treatment were given before surgery, 21 days as a course, with a regimen of camrelizumab (200 mg) and carboplatin on day 1 of each course, and on days 1/8/15 nab-paclitaxel (100 mg/m ² )

Camrelizumab (200 mg) and carboplatin were administered on day 1 of each cycle, and nab-paclitaxel (100 mg/m ² ) was administered on days 1/8/15

Pathological response in 51 patients

A total of 60 patients were enrolled between November 20, 2019, and December 22, 2020
.

Fifty-five (91.

Twenty (39.

Treatment-Related Adverse Reactions

Fifty-eight (96.
7%) patients experienced any grade of treatment-related adverse events (TRAEs), the most common of which was leukopenia (86.
7%)
.

Thirty-four (56.

In conclusion, this study demonstrated the strong antitumor activity of camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety issues
.

Combination regimen of camrelizumab with chemotherapy is a promising neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma

Robust antitumor activity of camrelizumab in combination with chemotherapy in locally advanced esophageal squamous cell carcinoma without unexpected safety concerns

Original source:

Liu Jun,Yang Yang,Liu Zhichao et al.

Liu Jun,Yang Yang,Liu Zhichao et al.
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.
[J] .
J Immunother Cancer, 2022, 10: https:/ /doi.
org/10.
1136/jitc-2021-004291.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.